PTO/AIA/96 (08-12)
`Approved for use through 11/30/2020. OMB 0651-0031
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`
`STATEMENT UNDER 37 CFR 3.73(c)
`Applicant/Patent Owner; GlaxoSmithKline Intellectual Property (No.3) Limited
`
`Application No./Patent No.: 17/362,063
`Filed/Issue Date: 2921-06-29
`
`Titled. SELECTIVE P2X3 MODULATORS
`GlaxoSmithKline Intellectual Property (No.3) Limited a corporation
`
`(Nameof Assignee)
`(Type of Assignee, e.g., corporation, partnership, university, government agency,etc.)
`
`states that, for the patent application/patent identified above, it is (choose one of options 1, 2, 3 or 4 below):
`
`1.
`
`The assignee of the entire right, title, and interest.
`
`2. [| An assigneeof less than the entireright, title, and interest (check applicable box):
`|_| The extent (by percentage)of its ownershipinterestis
`%. Additional Statement(s) by the owners
`holding the balance of the interest must be submitted to account for 100% of the ownership interest.
`L] There are unspecified percentages of ownership. Theother parties, including inventors, who together ownthe entire
`right, title and interest are:
`
`Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the entire
`right, title, and interest.
`3. L] The assignee of an undividedinterestin the entirety (a complete assignmentfrom oneofthe joint inventors was made).
`The other parties, including inventors, who together own the entireright, title, and interest are:
`
`
`
`Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the entire
`right, title, and interest.
`4. C The recipient, via a court proceeding orthe like (e.g., bankruptcy, probate), of an undividedinterestin the entirety (a
`complete transfer of ownership interest was made}. The certified document(s) showing the transfer is attached.
`
`The interest identified in option 1, 2 or 3 above (not option 4) is evidenced by either (choose one of options A or B below):
`
`A.[] An assignmentfrom the inventor(s) of the patent application/patentidentified above. The assignment wasrecordedin
`the United States Patent and Trademark Office at Reel
`, Frame
`, or for which a copy
`thereof is attached.
`
`B.
`
`A chain oftitle from the inventor(s), of the patent application/patent identified above, to the current assigneeasfollows:
`
`1. From: Kemal Payza To: NEOMED INSTITUTE
`
`The document was recorded in the United States Patent and Trademark Office at
`Ree! 057639
`0273
`, or for which a copy thereofis attached.
`, Frame
`2. From: D- Garceau, A. Matzouranis,R. Bellini, N. Chauret 75. Bellus Health Cough Inc.
`
`The document was recorded in the United States Patent and Trademark Office at
`Reel 057639
`, Frame 0491
`, or for which a copy thereofis attached.
`
`[Page 1 of 2]
`This collectionof information is required by 37CFR 3.73(b). The informationis required to obtain or retain a benefit by the public whichis tofile (and by the USPTO to
`process) an application.Confidentiality isgoverned by 35U.S.C. 122 and37 CFR 1.11and 1.14.This collection is estimated to take 12 minutes to complete, including
`gathering,preparing, and submitting the completed applicationform to the USPTO. Time will vary depending uponthe individual case. Any comments on the amount
`of time you require to complete this form and/or suggestions for reducing this burden, should besent to the Chief Information Officer, U.S. Patent and Trademark
`Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETEDFORMSTO THIS ADDRESS. SEND
`TO: Commissionerfor Patents, P.O. Box 1450, Alexandria, VA22313-1450 .
`
`Ifyou need assistance in completing the form, call 1-800-PTO-9199 and select option 2.
`
`
`
`PTO/AIA/96 (08-12)
`Approved for use through 11/30/2020. OMB 0651-0031
`U.S. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit displays a valid OMB control number.
`
`STATEMENT UNDER 37 CFR 3.73(c)
`
`: Susan E. Browne
`
`To: TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D,INC.
`
`The document was recorded in the United States Patent and Trademark Office at
`Reel 057639
`, Frame 0630
`, or for which a copy thereofis attached.
`. TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. +). NEOMED INSTITUTE
`
`The document was recorded in the United States Patent and TrademarkOffice at
`Reel 057639
`, Frame 0717
`, or for which a copy thereofis attached.
`NEOMED INSTITUTE
`To: Bellus Health Cough Inc.
`
`The document was recorded in the United States Patent and TrademarkOffice at
`Reel 064530
`Frame 0687
`
`, or for which a copy thereofis attached.
`To: Bellus Health Inc.
`
`
`
`The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.
`/W. Brett Stauffer/
`March 18, 2024
`
`
`Signature
`Date
`W. Brett Stauffer
`68,718
`
`Printed or Typed Name
`Title or Registration Number
`
`. Bellus Health Cough Inc.
`
`The document was recorded in the United States Patent and TrademarkOffice at
`Reel 064531
`, Frame 0830
`, or for which a copy thereofis attached.
`
`Additional documents in the chain oftitle are listed on a supplemental sheet(s).
`
`As required by 37 CFR 3.73(c)(1)(i), the documentary evidence of the chain oftitle from the original owner to the
`assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.
`
`[NOTE: A separate copy(i.e., a true copy of the original assignment document(s)) must be submitted to Assignment
`Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]
`
`[Page 2 of 2]
`
`
`
`SUPPLEMENTAL PAGE 1 of 1
`
`STATEMENT UNDER 37 C.F.R. § 3.73(c), continued
`
`7.
`
`From: BELLUS HEALTH INC.
`
`To: 14245563 Canada Inc.
`
`The document was recorded in the United States Patent and Trademark Office at Reel 065117,
`Frame 0909,or a copyis attached.
`
`8.
`
`From: 14245563 Canada Inc.
`
`To: ID Biomedical Corporation of Quebec
`
`The document was recorded in the United States Patent and Trademark Office at Reel 066353,
`Frame 0331, or a copyis attached.
`
`8.
`
`From: ID Biomedical Corporation of Quebec
`
`To:
`
`GlaxoSmithKline Intellectual Property
`(No.3) Limited
`
`The document was recorded in the United States Patent and Trademark Office at Reel 066353,
`Frame 0356,or a copyis attached.
`
`
